Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Levonorgestrel (LNG) Clear all
Completed Phase 3 Interventional

Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women

NCT02403401
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel (BAY98-7196)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
1,471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
79
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

NCT06380205
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Mirena Extension Trial

NCT02985541
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
49
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 6, 2026, 4:09 PM EDT
Withdrawn Phase 4 Interventional

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

NCT01941134
View directory record Official record
Conditions
Bariatric Surgery Candidate, Contraception
Interventions
ethinyl estradiol-levonorgestrel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

NCT00394771
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
DR-1031, Seasonale®, Portia®
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02824224
View directory record Official record
Conditions
Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions
Tamoxifen, Placebo (for Tamoxifen)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

NCT01166412
View directory record Official record
Conditions
Contraception
Interventions
levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2, levonorgestrel patch with BMI <32 kg/m2
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Aurora, Colorado • New York, New York • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception

NCT01240811
View directory record Official record
Conditions
Genital Tract Mucosal Immunity, Genital Tract Microflora
Interventions
IUD placement, Levonorgestrel IUD, Copper T380A IUD
Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

NCT03279120
View directory record Official record
Conditions
Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
Interventions
TFV/LNG IVR, Placebo
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Continuous Oral Contraceptives and Doxycycline

NCT00480532
View directory record Official record
Conditions
Contraceptives, Oral
Interventions
Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

NCT03455075
View directory record Official record
Conditions
Healthy, Men, Male Contraception
Interventions
Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

NCT03984825
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Portia
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 6, 2026, 4:09 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

NCT03537768
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EC PK in Women With Normal and Obese BMI

NCT02689804
View directory record Official record
Conditions
Contraception
Interventions
LNG-EC, UPA-EC
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 6, 2026, 4:09 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

NCT06671405
View directory record Official record
Conditions
Dyslipidaemia
Interventions
AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LNG-IUS at 2 Weeks Postpartum

NCT02121067
View directory record Official record
Conditions
Contraception, Malposition of Intrauterine Contraceptive Device
Interventions
Levonorgestrel Intrauterine System (LNG-IUS)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 6, 2026, 4:09 PM EDT
Recruiting Phase 4 Interventional

Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start

NCT05444582
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel 52 MG Intrauterine System
Drug
Lead sponsor
University of Utah
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
San Jose, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 6, 2026, 4:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion

NCT00635362
View directory record Official record
Conditions
Healthy
Interventions
Levonorgestrel-releasing intrauterine system (LNG-IUS)
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

NCT06657105
View directory record Official record
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186
View directory record Official record
Conditions
Hemostasis, Oral Contraceptive
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Levonorgestrel (LNG)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 6, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study

NCT00528112
View directory record Official record
Conditions
Contraception
Interventions
LCS12, LCS16
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
2,885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
57
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 6, 2026, 4:09 PM EDT